ATE543492T1 - Behandlung von lungenkrebs - Google Patents

Behandlung von lungenkrebs

Info

Publication number
ATE543492T1
ATE543492T1 AT07849582T AT07849582T ATE543492T1 AT E543492 T1 ATE543492 T1 AT E543492T1 AT 07849582 T AT07849582 T AT 07849582T AT 07849582 T AT07849582 T AT 07849582T AT E543492 T1 ATE543492 T1 AT E543492T1
Authority
AT
Austria
Prior art keywords
lung cancer
treatment
fts
disclosed
analogs
Prior art date
Application number
AT07849582T
Other languages
English (en)
Inventor
Yoel Kloog
Adi Zundelevich
Roni Haklai
Original Assignee
Univ Ramot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ramot filed Critical Univ Ramot
Application granted granted Critical
Publication of ATE543492T1 publication Critical patent/ATE543492T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT07849582T 2006-12-19 2007-12-17 Behandlung von lungenkrebs ATE543492T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87591506P 2006-12-19 2006-12-19
PCT/IL2007/001556 WO2008075342A1 (en) 2006-12-19 2007-12-17 Treatment of lung cancer

Publications (1)

Publication Number Publication Date
ATE543492T1 true ATE543492T1 (de) 2012-02-15

Family

ID=39203260

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07849582T ATE543492T1 (de) 2006-12-19 2007-12-17 Behandlung von lungenkrebs

Country Status (6)

Country Link
US (3) US8232253B2 (de)
EP (1) EP2094260B1 (de)
AT (1) ATE543492T1 (de)
CA (1) CA2672839C (de)
MX (1) MX2009006574A (de)
WO (1) WO2008075342A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8278349B2 (en) 2005-11-28 2012-10-02 Ramot At Tel-Aviv University Ltd. Cancer treatment using FTS and 2-deoxyglucose
MX2009006574A (es) * 2006-12-19 2009-07-02 Univ Ramot Tratamiento de cancer de pulmon.
JP2013508458A (ja) * 2009-10-26 2013-03-07 ラモット・アット・テル−アヴィヴ・ユニヴァーシティ・リミテッド Ftsとhdac阻害剤との組合せを用いたがん治療
CN110441343A (zh) 2011-03-22 2019-11-12 通用医疗公司 利用磁共振检测目的物
US9738614B2 (en) 2011-10-07 2017-08-22 Pisces Therapeutics, Llc Malignant and non-malignant disease treatment with Ras antagonists
RU2632097C2 (ru) 2011-10-07 2017-10-02 ПАЙСИЗ ТЕРАПЬЮТИКЗ ЭлЭлСи Лечение злокачественных и незлокачественных заболеваний с помощью антагонистов ras
US9474730B2 (en) * 2012-04-30 2016-10-25 Board Of Regents Of The University Of Texas System Methods and compositions for use with K-ras mediated disorders
CN104292140B (zh) * 2014-08-25 2016-06-29 南通大学 含有查尔酮骨架的法尼基硫代水杨酸类似物及制备方法和用途
CN104292139B (zh) * 2014-08-25 2016-04-13 南通大学 法尼基硫醚取代的查尔酮衍生物及制备方法和用途
US10561628B2 (en) 2015-03-19 2020-02-18 Daiichi Sankyo Company, Limited Solid preparation including antioxidant

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL107587A (en) 1993-11-12 1998-08-16 Univ Ramot Farnesyl geranyl or geranyl-geranyl derivatives pharmaceutical compositions containing them and methods for their preparation
US20020115696A1 (en) * 1999-06-18 2002-08-22 Yoel Kloog Treatment of post-angioplasty restenosis and atherosclerosis with ras antagonists
EP1325116A2 (de) * 2000-10-04 2003-07-09 RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT LTD. Isoprenoid-abhängige ras-ankerproteine (idra)
ES2414861T3 (es) * 2004-08-18 2013-07-23 Kadmon Corporation, Llc Uso del FTS para el tratamiento de trastornos malignos
US8278349B2 (en) * 2005-11-28 2012-10-02 Ramot At Tel-Aviv University Ltd. Cancer treatment using FTS and 2-deoxyglucose
MX2009006574A (es) * 2006-12-19 2009-07-02 Univ Ramot Tratamiento de cancer de pulmon.

Also Published As

Publication number Publication date
CA2672839C (en) 2012-07-03
EP2094260A1 (de) 2009-09-02
WO2008075342A1 (en) 2008-06-26
US20140088123A1 (en) 2014-03-27
US20100136138A1 (en) 2010-06-03
US8232253B2 (en) 2012-07-31
MX2009006574A (es) 2009-07-02
US20120294957A1 (en) 2012-11-22
EP2094260B1 (de) 2012-02-01
CA2672839A1 (en) 2008-06-26

Similar Documents

Publication Publication Date Title
MX2009006574A (es) Tratamiento de cancer de pulmon.
EA201490254A1 (ru) Комбинированное лечение гепатита с
EA200970932A1 (ru) Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа
EA200970935A1 (ru) Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
EA201100971A1 (ru) Производные пиримидининдола для лечения злокачественного новообразования
MX2018012165A (es) Metodos de tratamiento de canceres pediatricos.
EA201301078A1 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
UA114726C2 (uk) 1,4-дизаміщені аналоги піридазину та способи лікування пов'язаних з дефіцитом smn станів
AR072442A1 (es) Metodo para la terapia del cancer, uso, kit
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
ECSP099436A (es) Acilaminopirazoles como inhibidores de fgfr
RU2013148721A (ru) Комбинации соединений, ингибирующих акт и вемурафениба и способы их применения
EA201391286A1 (ru) Лечение солидных опухолей
EA200971107A1 (ru) Катехоламиновые производные, полезные для лечения болезни паркинсона
EA201071038A1 (ru) Производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
AR057295A1 (es) Combinaciones y procedimientos para usar un compuestos de indolinona
BRPI0908635B8 (pt) composto e/ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica
IL192100A0 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
TNSN07419A1 (en) Methods for treating drug resistant cancer
MX2009005798A (es) Recuperacion de apoplejia.
EA200970345A1 (ru) Лечение гипербилирубинемии новорожденных с использованием низких дозировок станнсопорфина
EA201071352A1 (ru) Трициклические азотсодержащие соединения и их применение в качестве бактерицидных средств
EA201490199A1 (ru) Терапевтические способы
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.